Equities

Intellipharmaceutics International Inc

Intellipharmaceutics International Inc

Actions
  • Price (EUR)0.045
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-34.78%
  • Beta--
Data delayed at least 15 minutes, as of Mar 06 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Nov 30 2022202220212020
ASSETS
Cash And Short Term Investments0.080.770.20
Total Receivables, Net0.270.271.05
Total Inventory--00.11
Prepaid expenses0.140.060.12
Other current assets, total------
Total current assets0.491.101.48
Property, plant & equipment, net0.940.991.91
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets------
Total assets1.432.103.39
LIABILITIES
Accounts payable3.763.784.10
Accrued expenses6.054.543.60
Notes payable/short-term debt2.161.921.96
Current portion long-term debt/capital leases------
Other current liabilities, total0.030.020.04
Total current liabilities12109.70
Total long term debt000
Total debt2.161.921.96
Deferred income tax------
Minority interest------
Other liabilities, total------
Total liabilities12109.70
SHAREHOLDERS EQUITY
Common stock494946
Additional paid-in capital454544
Retained earnings (accumulated deficit)(105)(102)(97)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.280.280.28
Total equity(11)(8.16)(6.31)
Total liabilities & shareholders' equity1.432.103.39
Total common shares outstanding333324
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.